26
|
Siu A, Chan S, Cheung M, Mo C, Lai S, Shek D. Predictors of psychosocial adaptation and mental wellbeing among people with chronic illness and disabilities in a chinese context. Eur Psychiatry 2021. [PMCID: PMC9480170 DOI: 10.1192/j.eurpsy.2021.2094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Introduction The process of adjustment to disability and illness among people with chronic illness and disabilities (CID) impacts on motivation for rehabilitation illness self-management, and psychological well-being. It involves a complex interplay of biopsychosocial factors, and was seldom examined in the Chinese context. Objectives Identify the predictors of mental well-being of people with from a set of variables including illness and social support, functional abilities, coping strategies, resilience. Examine how these factors interact in determining psychosocial adaptation and mental well-being by structural equations modelling (SEM). Methods We conducted a survey of people with CID, who were recruited from community-rehabilitation settings and self-help groups (N = 244). The research questionnaire collected basic demographic information, illness-related variables (e.g. pain, fatigue, functional limitations), and RIDI), social support, measures of resilience, coping, psychosocial ad as predictors, and mental well-being. Results Of General Linear Model (GLM) revealed that males have better adaptation than females. Resilience, social coping, & active problem solving are significant predictors of adaptation (Table 1), while age, breathing, pain, resilience, avoidance coping, are predictors of maladaptation (Table 2). A SEM was tested to examine the interaction among the predictors and outcome of adaptation and mental well-being (Figure 1), and the model fit was fair (CFI = 0.89; RMSEA = 0.09) Conclusions The results indicated that there are gender differences in adaptation. While all the hypothesized groups of variables contributed to mental well-being of people with CID. Resilience, illness variables, and some forms of coping are closely linked to adaptation and maladaptation. Disclosure No significant relationships.
Collapse
|
27
|
Fennell D, Ottensmeier C, Califano R, Hanna G, Ewings S, Hill K, Wilding S, Danson S, Nye M, Steele N, Johnson L, Lord J, Middleton C, Marwood E, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester J. PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.323] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
28
|
Fung MKL, Chan S, Sun S, Zhang PD, Leung GKK, Chan GCF. HGG-27. ANTI-CANCER POTENTIAL OF ARGINASE FOR HIGH-GRADE GLIOMA IN VITRO & IN-VIVO. Neuro Oncol 2020. [PMCID: PMC7715630 DOI: 10.1093/neuonc/noaa222.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
High-grade glioma is currently incurable. It was reported that glioma may be auxotrophic to arginine due to the lack of urea cycle genes expressions, suggesting arginase may be a potential agent for high grade glioma. AIM: We investigated the efficacy of pegylated arginase I (pegArg-I) or in combination with other anti-cancer drugs for high-grade glioma in vitro and in vivo.
METHODS
4 high-grade glioma cell lines (U87, U373, U138, D54) were treated with pegArg-I in vitro. The molecular mechanism of pegArg-I-induced cytotoxicity was tested in U87. The ultra-morphological changes of pegArg-I-treated U87 was investigated by both scanning and transmission electron microscopy. Orthotopic glioma xenograft model with luciferase-transfected U87 cell line was tested for anti-cancer efficacy of peg-Arg I in vivo.
RESULTS
We showed that pegArg-I induced significant cell death in all 4 cell lines in vitro. Temozolomide, difluoromethyornithine and chloroquine (CQ) were then tested together with pegArg-I in U87 in vitro. We found that only CQ showed additive effect with pegArg-I against glioma in vitro. Such additive cytotoxic effect may be associated with enhanced autophagy and necrosis as shown in transmission electron microscopy and autophagy markers’ expression by Western blotting. PegArg-I prolonged the survival of glioma mice, suggesting its possible anti-glioma efficacy. However, CQ+pegArg-I didn’t show further significant anti-cancer efficacy in vivo.
CONCLUSION
PegArg-I may be useful in slowing the progression of glioma, but additional drug candidate which works synergistically with pegArg-I remains to be explored.
Collapse
|
29
|
Soni V, Chan S, Lee A, Alventosa S, Ashamalla H, Yanagihara T. Determining The Frequency And Underlying Factors Of Brain Metastasis Symptoms. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Wang H, Mendez LC, Morton G, Loblaw A, Mesci A, Chung HT, Chan S, Huang X, Downes MR, Vesprini D, Liu SK. Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study. Radiother Oncol 2020; 155:80-85. [PMID: 33172830 DOI: 10.1016/j.radonc.2020.10.029] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 10/13/2020] [Accepted: 10/19/2020] [Indexed: 10/23/2022]
Abstract
This exploratory study evaluates immunological changes in high-risk Gleason 9 prostate cancer patients treated with EBRT+BT compared to EBRT alone. Notably, BT demonstrates the potential to elicit a T cell response which may support further investigation using circulating immune cells as predictive and prognostic biomarkers for radiotherapy response.
Collapse
|
31
|
Burrows F, Shivani M, Wang Z, Chan S, Gilardi M, Gutkind S. Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31191-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Chow J, Tam A, Cheung K, Lee V, Chiang C, Tong M, Wong E, Cheung A, Chan S, Lai J, Ngan R, Ng W, Lee A, Au K. 913MO Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
33
|
Chan S, Chiang C, Lee S, Wong I, Choi H. P-259 Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
34
|
Cheong CS, Aung AT, Chan S, Lee C. 1013 Cardiovascular Biomarkers and Pathophysiological Insights into Obstructive Sleep Apnea During Acute Coronary Syndrome. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Obstructive sleep apnea (OSA) is prevalent and carries prognostic implication in patients with acute coronary syndrome (ACS). The relative contribution of pathophysiological mechanisms in ACS towards OSA is not well-studied. We examined the correlation between severity of OSA and myocardial necrosis, inflammation, wall stress, and fibrosis.
Methods
A total of 89 patients admitted with ACS underwent an overnight sleep study during index admission. Plasma levels of peak troponin I, high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and suppression of tumorigenicity 2 (ST2) were prospectively analyzed. Two patients diagnosed with central sleep apnea were excluded.
Results
The recruited patients were divided into no (AHI <5 events/hour, 9.2%), mild (5-<15, 27.6%), moderate (15-<30, 21.8%), and severe (≥30, 41.4%) OSA. The respective Epworth Sleepiness Scale scores were 3.8±3.7, 5.3±4.9, 4.0±2.8, and 5.5±4.5 (p=0.734). Compared to the no, mild and moderate OSA groups, the severe OSA group had a higher body mass index (p=0.005). They were also more likely to present with ST-segment elevation ACS (vs non-ST-segment elevation ACS) (p=0.041), have undergone previous coronary artery bypass grafting (p=0.013), demonstrate complete coronary occlusion during baseline coronary angiography (p=0.049), and have a larger left atrium diameter measured on echocardiography (p=0.029). Likewise, the severe OSA group had higher plasma levels of troponin I (10584±13078, 11699±20130, 19280±30670, 37571±31269 µg/L; p=0.017), hs-CRP (8.1±9.2, 23.1±52.3, 9.3±17.1, 39.4±44.7 mg/L; p=0.004), and NT-proBNP (667±604, 765±856, 636±728, 1395±1220 pg/mL; p=0.004), but not ST2 (p=0.10). After adjusting for the effects of the confounding variables, severe OSA was independently associated with troponin I (i.e., myocardial necrosis; OR 1.00003, 95% CI 1.000013-1.000048; p=0.001) and NT-proBNP (i.e., myocardial wall stress; OR 1.00081, 95% CI 1.00021-1.00141; p=0.008).
Conclusion
Severe OSA during the acute phase of ACS was associated with extensive myocardial necrosis and myocardial wall stress, but not with inflammation and myocardial fibrosis.
Support
Nil
Collapse
|
35
|
Zhuang K, Patel A, Tay K, Irani F, Matchar D, Sivapragasam N, Pua U, Sum L, Tze Tec C, Tan G, Chan E, Win H, Burgmans M, Gogna A, Damodharan K, Chan S, Too C, Karaddi Venkatanarasimha N, Quek L, Gummalla K, Siew Ping C, Tan B. 4:12 PM Abstract No. 50 Quality of life outcomes from a randomized controlled trial comparing drug-eluting balloon to conventional balloon angioplasty for below-the-knee arteries in patients with critical limb ischemia. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
36
|
Tan Z, Chan S, Bin Abdul Rahman A, Chandramohan S, Damodharan K, Gogna A, Irani F, Leong S, Lo R, Karaddi Venkatanarasimha N, Patel A, Tan B, Too C, Zhuang K, Bin Sulaiman M, Tan C, Tze Tec C, Win H. 3:18 PM Abstract No. 15 Cutting balloon followed by drug-eluting balloon angioplasty for recurrent venous lesions in dialysis access; interim analysis of a single-arm prospective observational study. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
37
|
Li A, Chan S, Thung KH. Pre-operative CT localization for patients with subsolid opacities expecting video-assisted thoracoscopic surgery-single center experience of fluorescent iodized emulsion and hook-wire localization technique. Br J Radiol 2020; 93:20190938. [PMID: 32023087 DOI: 10.1259/bjr.20190938] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVE To describe our clinical experience of using combination of fluorescent iodized emulsion, indocyanine green & lipiodol, and hook-wire in pre-operative CT localization of patients with subsolid lung lesions prior to video-assisted thoracoscopic surgery (VATS). METHODS A retrospective review between June 2018 and July 2019 of consecutive Chinese patients whom underwent VATS for subsolid lung lesions with pre-operative CT localization done with combination of fluorescent iodized emulsion and hook-wire technique in a tertiary hospital (Tuen Mun Hospital, Hong Kong SAR). The duration and complications related to the localization procedure were recorded The clinical records, operative findings and pathology reports were retrieved from the hospital electronic clinical management system. RESULTS Combination fluorescent iodized emulsion with hook-wire enabled accurate localization and resection of all subsolid lung lesions in VATS. No major complications were reported. CONCLUSION Combination of fluorescent iodized emulsion and hook-wire placement under CT guidance is a simple, safe and cost- effective procedure that enabled accurate localization and resection of subsolid nodule in VATS. ADVANCES IN KNOWLEDGE VATS has been the mainstay for indeterminate pulmonary nodules for diagnostic and/or curative purpose. The main problem that surgeons may encounter during operation is the difficulty in locating the target lesion particularly for subsolid lesions. Many pre-operative localization methods have been developed in this regard. With the novel technique that we described, we were able to overcome disadvantages of most described methods.
Collapse
|
38
|
Reddy V, Myers B, Brownstone N, Thibodeaux Q, Chan S, Liao W, Bhutani T. Update on Sleep and Pulmonary Comorbidities in Psoriasis. CURRENT DERMATOLOGY REPORTS 2020. [DOI: 10.1007/s13671-020-00293-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Johnson M, Spira A, Carbone D, Drake C, Henick B, Ingham M, Caldwell K, Chan S, Hart M, Malloy A, Maloney E, Palmer C, Yang A, Zhong M, Basciano P, Bournazou E, Ferguson A, Catenacci D. First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz451.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Merle P, Kulkarni A, Ryoo BY, Cheng AL, Kudo M, Bouattour M, Lim H, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan S, Daniele B, Norquist J, Chen E, Siegel A, Zhu A, Finn R. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Pho Y, Nhem S, Sok C, By B, Phann D, Nob H, Thann S, Yin S, Kim C, Letchford J, Fassier T, Chan S, West TE. Melioidosis in patients with suspected tuberculosis in Cambodia: a single-center cross-sectional study. Int J Tuberc Lung Dis 2019; 22:1481-1485. [PMID: 30606321 DOI: 10.5588/ijtld.17.0294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING Melioidosis-Burkholderia pseudomallei infection-is increasingly recognized in Cambodia, a country with a high incidence of tuberculosis (TB). Melioidosis and TB can be clinically indistinguishable. OBJECTIVE To quantify the proportion of patients with clinically suspected TB who had melioidosis by testing sputum for B. pseudomallei. DESIGN This was a prospective, 6-month cross-sectional single-center study at a Cambodian provincial referral hospital among patients with suspicion of TB who provided sputum specimens for testing. TB was diagnosed using sputum Xpert® MTB/RIF molecular assay or culture; melioidosis was diagnosed using sputum culture for B. pseudomallei. RESULTS Of 404 patients evaluated for possible TB, 52 (12.9%, 95%CI 9.8-16.5) had TB. Four patients (1.0%, 95%CI 0.3-2.5) had melioidosis; none had concurrent TB or an existing medical risk factor for melioidosis, although two were farmers, an occupational risk factor. CONCLUSION One per cent of patients being evaluated for TB at a Cambodian provincial referral hospital had culture-proven respiratory melioidosis, a highly lethal infection. None had previously recognized medical conditions that would increase their risk of melioidosis. Testing for melioidosis should be considered in patients presenting with suspected TB in Cambodia.
Collapse
|
42
|
Cheung P, Morton G, Chung H, Vesprini D, Chu W, Liu S, Tseng C, Sahgal A, Soliman H, Myrehaug S, Szumacher E, Chung P, Helou J, Emmenegger U, Erler D, Mamedov A, Chan S, Zhang L, Loblaw D. Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1886] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
43
|
Wang S, Wang Y, Shen D, Zhang L, Chen W, Chan S, Guan Z, Song C, Gao B. ZB transposon and chicken vasa homologue (Cvh) promoter interact to increase transfection efficiency of primordial germ cells in vivo. Br Poult Sci 2019; 60:724-728. [PMID: 31267766 DOI: 10.1080/00071668.2019.1639138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. In order to increase the efficiency of generating transgenic chicken, this trial focused on two points: primordial germ cells (PGCs)transfection in vivo and a germline-specific promoter.2. In order to transfect PGCs in vivo, two plasmids (pZB-CAG-GFP, pCMV-ZB)were co-injected into chicken embryos via the subgerminal cavity at Hamburger and Hamilton (HH) stage 2-3 or via blood vessel at HH stage 13-14. Results showed that the percentage of GFP+ embryos, viability and hatching rate of embryos injected at HH stage 13-14 were significantly higher than that at HH stage 2-3.3. Two plasmid transposon systems were used for chicken embryo micro-injections. The donor plasmid, with a green fluorescent protein (GFP) reporter gene, was mediated by the ZB transposon. The helper plasmid was a transposase expression vector driven by the promoter of the chicken vasa homologue (Cvh) gene or Human cytomegalovirus (CMV) promoter. Results showed that 60.98% of gonads in Cvh group expressed GFP, which was 52.50% higher than seen in the CMV group. Only gonad tissue from the Cvh group showed any GFP signal, whereas both gonads and other tissues in the CMV group showed green fluorescence.4. The data suggested that ZB transposon-mediated gene transfer was efficient for transfecting PGCs in vivo; the Cvh promoter drove the transposase gene specifically in the germline and increased the efficiency of germline transmission. Blood vessels injection at HH stage 13-14 may be a more efficient route for PGCs transfection in vivo.
Collapse
|
44
|
Lim R, Li A, Kusuma G, Chan S, McPhee G, Fitzpatrick I, Wilson S, James D. Enabling clinical trials in an academic GMP setting through use of closed, semi-automated manufacturing of allogeneic amniotic epithelial cells. Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.03.370] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Hopman H, Chan S, Chu W, Lu H, Lam L, Mak A, Kahn R, Neggers S. Resting-state fMRI biomarkers and effects of transcranial magnetic stimulation in treatment-refractory depression. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
46
|
Chow E, Chan S, Yao Z, Sutradhar R, Lee J, Wan BA, Paszat L. Abstract P3-12-05: Fractionation patterns in adjuvant breast radiotherapy in Ontario, Canada from 2009 to 2015. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To report the patterns of use of hypofractionated radiotherapy (HFRT) (≤16 fractions)in breast cancer and ductal carcinoma in situ (DCIS) patients in Ontario, Canada from 2009 to 2015 and identify factors related to HFRT use.
Methods: A retrospective cohort study of Ontario women diagnosed with breast cancer or DCIS followed by adjuvant breast or chest wall radiation (RT) from 2009 to 2015 was conducted using data from the Institute for Clinical Evaluative Sciences (ICES). Logistic regression models were used to identify factors associated with HFRT use. Physician was included as a random effect. To calculate the potential amount of time that could be saved if all patients were to receive 16 fractions of HFRT, the number of extra RT treatments after the 16th visit was multiplied by the median amount of time spent to treat one patient at our cancer centre (8.76 minutes). This time was found with Sunnybrook Health Sciences Centre data collected from October 2017 to March 2018 (n=523) and represents the amount of time from when a patient enters the RT unit for treatment setup, until the RT beam is turned off.
Results: A total of 42,072 patients were included. Most patients were aged between 50 and 69 years old (56.7%) with stage I or II breast cancer (74.6%) and had breast conserving surgery (BCS) (76.9%). Half previously received chemotherapy and 7.9% were DCIS patients. Use of sequential boost, simultaneous boost, and regional nodal RT was 17.2%, 3.1%, and 31.7% respectively. Institutional variation in HFRT use ranged from 27.5% to 71.6%. HFRT use has increased in all patient populations over the study period. HFRT use was more common in breast cancer and DCIS patients with BCS than in chest wall and nodal RT. Simultaneous boost (OR=0.09), nodal RT (OR=0.08), previous chemotherapy (OR=0.7), stage 0, II, and III breast cancer (OR=0.06 relative to stage I), were correlated with less HFRT use. Older age, later year of diagnosis, sequential boost (OR=0.09), BCS and no surgery (OR=1.2, 1.5 relative to mastectomy) were correlated with higher HFRT use. Institution was significantly correlated to HFRT use. The variance estimate for the physician random effect was 0.33 (p<0.0001). For breast cancer patients with BCS and breast RT specifically, 62,396 extra visits occurred from 2009 to 2015, corresponding to ˜9100 hours of treatment if all patients received HFRT. For the entire patient population, a total of 190,726 extra visits occurred or ˜27,900 hours.
Trends in the use of HFRT (%) from 2009 to 2015 for DCIS and breast cancer patients in Ontario.YearStage I-IV + BCS + Breast RTStage I-IV + BCS + Breast + Nodal RTStage I-IV + Mastectomy + Breast RTStage I-IV + Mastectomy + Breast + Nodal RTDCIS + BCS200962.610.329.09.545.2201062.06.323.76.951.2201162.24.121.34.752.7201263.79.621.711.452.0201365.112.629.315.057.3201469.37.835.415.164.5201573.711.839.217.573.4BCS: breast conserving surgery, RT: radiation treatment
Conclusions: HFRT use in Ontario has increased over time for all patient populations, and reflects the current evidence supporting HFRT in different patient populations, with lower HFRT use seen in chest wall and nodal RT and higher HFRT use in early-stage breast cancer patients with BCS.
Citation Format: Chow E, Chan S, Yao Z, Sutradhar R, Lee J, Wan BA, Paszat L. Fractionation patterns in adjuvant breast radiotherapy in Ontario, Canada from 2009 to 2015 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-05.
Collapse
|
47
|
Alabdullah ML, Ahmad DA, Moseley P, Madhusudan S, Chan S, Rakha E. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer. J OBSTET GYNAECOL 2019; 39:522-528. [PMID: 30712414 DOI: 10.1080/01443615.2018.1534091] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Ovarian cancer is associated with the highest mortality rate among gynaecologic malignancies. There is a need to refine the classification of ovarian cancer and identify novel targets. The mammalian target of rapamycin (mTOR) pathway has a crucial role in the pathogenesis and progression of ovarian cancer. This study aims to investigate the prognostic role of p-mTOR and its major downstream effectors p-4EBP1 (eukaryotic initiation factor 4E-binding protein 1) and p-P70S6K (ribosomal protein S6 kinase) in ovarian cancer. p-mTOR, p-4EBP1 and p-P70S6K protein expression was assessed on 195 consecutive ovarian epithelial cancers and correlated to clinicopathological features and survival. We found that high cytoplasmic expression of p-4EBP1 and p-P70S6K was associated with a serous type carcinoma (p = .005) and an advanced FIGO stage (p = .012), respectively. Univariate outcome analysis showed an inverse association between a high expression of p-4EBP1 expression and overall ovarian cancer survival (OS; p = .005) and progression-free survival (PFS; p = .005). p-P70S6K showed an inverse association with PFS (p = .001). Multivariate analyses indicated that p-4EBP1 was an independent predictor of both OS and PFS (p = .016 and p = .041, respectively). Therefore, we concluded that p-4EBP1 high protein expression is an independent predictor of outcome in ovarian cancer patients. Therefore, it could be used as a potential biomarker for prognostic stratification and treatment decisions. Impact statement What is already known on this subject? The mammalian target of rapamycin (mTOR) pathway has a crucial role in the pathogenesis and progression of ovarian cancer. To-date, very limited knowledge is known about the importance of mTOR major downstream effectors p-4EBP1 (eukaryotic initiation factor 4E-binding protein 1) and p-P70S6K (ribosomal protein S6 kinase) in ovarian cancer. What do the results of this study add? In this study, we have provided further evidence of the adverse prognostic behaviour associated with the positive expression of p-mTOR and its major downstream effectors. Moreover and by performing multivariate analysis, we for the first time have proved that p-4EBP1 is an independent predictor of clinical outcome in ovarian cancer. What are the implications of these findings for clinical practice and/or further research? p-4EBP1 could be used as a potential biomarker for prognostic stratification and treatment decisions in ovarian cancer management.
Collapse
|
48
|
Wheeler J, Chan S, Harrigan PR, Becker M, Kasper K, Keynan Y. Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada. Int J STD AIDS 2018. [PMID: 29513131 DOI: 10.1177/0956462418760426] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
49
|
Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer 2018; 27:2699-2705. [DOI: 10.1007/s00520-018-4564-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Accepted: 11/20/2018] [Indexed: 12/29/2022]
|
50
|
van Dams R, Shaverdian N, Raghavan G, Chan S, Lee P. The Effect of SBRT Treatment Duration for Early Stage NSCLC on Control Rates, Survival and Toxicity. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|